Effect of Remimazolam on Postoperative Nausea and Vomiting

Completed 108 enrolled Inje University

RandomizedParallel-groupDouble-blindOther

Summary

The present trial is to study the effect of low dose remimazolam on postoperative nausea and vomiting (PONV) in patients at risks of PONV (women, postoperative use of opioid, nonsmokers) undergoing laparoscopic cholecystectomy.

Timeline

Start: 2022-04-13
Primary completion: 2024-10-31
Completion: 2024-10-31

Publications

Park S, Yon JH, Lee S, Kim KM, Jun IJ. Efficacy of intraoperative low-dose remimazolam as a third antiemetic agent for preventing early postoperative nausea in high-risk patient: A Randomized controlled trial. BMC Anesthesiol. 2025 Sep 2;25(1):442. doi: 10.1186/s12871-025-03332-3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Remimazolam	Small molecule	0.3 mg/kg	—

Indications

No indication recorded.